Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 9/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 9/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688994 | 0.85 | IKBKB (0.49) | MEN1CA1CA2KMT2A | |
| SCHEMBL27759717 | 0.85 | BCL2L1 (0.48) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL8046560 | 0.84 | PTPN1 (0.66) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL19100976 | 0.84 | CA1 (0.61) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL4863547 | 0.83 | AKR1C2 (0.62) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL27808113 | 0.82 | BCL2L1 (0.53) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL22732563 | 0.82 | KDM4E (0.54) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL8552828 | 0.82 | CA1 (0.64) | BCL2L1BADKDM4EALDH1A1CA1 | |
| SCHEMBL11411645 | 0.81 | TTR (0.70) | AKR1C2AKR1C1MCL1HMGB1CXCL12 | |
| SCHEMBL4123010 | 0.81 | PTPN1 (0.72) | AKR1C2AKR1C1HMGB1CXCL12PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| CN-101010083-A | Methods and reagents for the treatment of metabolic disorders | COMBINATORX INC (US) | 2007-08-01 | — | — | CN | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| CN-1867340-A | Topical use of halosalicylic acid derivatives | AVON PROD INC (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1694337-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005058230-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | AVON PRODUCTS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | NACA, TYR, PRKDC | AKR1C2 3506/4885AKR1C1 3549/4885MCL1 729/4885 |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | AKR1C2 359/4885AKR1C1 484/4885MCL1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.